相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of novel F508del-CFTR traffic correctors among triazole derivatives
Mafalda Bacalhau et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2023)
A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR
Jia Liu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A
Miqueias Lopes-Pacheco et al.
CELLS (2022)
Rectal organoid-guided CFTR modulator therapy restores lung function in a cystic fibrosis patient with the rare 1677delTA/R334W genotype
Georgia Mitropoulou et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers
Fabiana Ciciriello et al.
JOURNAL OF PERSONALIZED MEDICINE (2022)
Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis
Iris A. L. Silva et al.
JOURNAL OF PERSONALIZED MEDICINE (2022)
Novel CFTR modulator combinations maximise rescue of G85E and N1303K in rectal organoids
Marjolein M. Ensinck et al.
ERJ OPEN RESEARCH (2022)
Rescue of multiple class II CFTR mutations by elexacaftor plus tezacaftor plus ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
Onofrio Laselva et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic Fibrosis
Steven E. Van der Plas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of CFTR modulators for the treatment of cystic fibrosis
Miqueias Lopes-Pacheco et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR
Guido Veit et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids
Iris A. L. Silva et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries
Nataliya Volkova et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Mutation-specific dual potentiators maximize rescue of CFTR gating mutants
Guido Veit et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Miqueias Lopes-Pacheco
FRONTIERS IN PHARMACOLOGY (2020)
Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR
Miqueias Lopes-Pacheco et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Design, synthesis, structural characterization and in vitro evaluation of new 1,4-disubstituted-1,2,3-triazole derivatives against glioblastoma cells
Veronica D. da Silva et al.
BIOORGANIC CHEMISTRY (2019)
Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770
Han- Yeh et al.
JOURNAL OF GENERAL PHYSIOLOGY (2019)
Structural identification of a hotspot on CFTR for potentiation
Fangyu Liu et al.
SCIENCE (2019)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G. M. Heijerman et al.
LANCET (2019)
Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants
Puay-Wah Phuan et al.
SCIENTIFIC REPORTS (2019)
Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809
Jake E. Doiron et al.
CHEMISTRY-A EUROPEAN JOURNAL (2019)
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor
Patrick A. Flume et al.
JOURNAL OF CYSTIC FIBROSIS (2018)
Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators
Puay-Wah Phuan et al.
JOURNAL OF CYSTIC FIBROSIS (2018)
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
Leona Bessonova et al.
THORAX (2018)
1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & anti-inflammatory activity
Fatima Naaz et al.
BIOORGANIC CHEMISTRY (2018)
Identification and Characterization of Novel CFTR Potentiators
Maarten Gees et al.
FRONTIERS IN PHARMACOLOGY (2018)
Role of CFTR in epithelial physiology
Vinciane Saint-Criq et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
A common mechanism for CFTR potentiators
Han-I Yeh et al.
JOURNAL OF GENERAL PHYSIOLOGY (2017)
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Jennifer L. Taylor-Cousar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
Antoine Daina et al.
SCIENTIFIC REPORTS (2017)
The 1,2,3-triazole ring as a bioisostere in medicinal chemistry
Elisa Bonandi et al.
DRUG DISCOVERY TODAY (2017)
Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries
Xueshun Wang et al.
DRUG DISCOVERY TODAY (2016)
Synthesis of newer 1,2,3-triazole linked chalcone and flavone hybrid compounds and evaluation of their antimicrobial and cytotoxic activities
Rama Kant et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synthesis and biological evaluation of phenyl-1H-1,2,3-triazole derivatives as anti-inflammatory agents
Tae Woo Kim et al.
BIOORGANIC CHEMISTRY (2015)
Combination of Correctors Rescue ΔF508-CFTR by Reducing Its Association with Hsp40 and Hsp27
Miqueias Lopes-Pacheco et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis
Nikhil T. Awatade et al.
EBIOMEDICINE (2015)
Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
Fredrick Van Goor et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
Kris De Boeck et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Design, synthesis, and antiviral activity of new 1H-1,2,3-triazole nucleoside ribavirin analogs
Maria de Lourdes G. Ferreira et al.
MEDICINAL CHEMISTRY RESEARCH (2014)
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Johanna F. Dekkers et al.
NATURE MEDICINE (2013)
Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle
Kang-Yang Jih et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner
Paul D. W. Eckford et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Haihui Yu et al.
JOURNAL OF CYSTIC FIBROSIS (2012)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
N-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a New Scaffold that Provides Rapid Access to Antimicrotubule Agents: Synthesis and Evaluation of Antiproliferative Activity Against Select Cancer Cell Lines
Jonathan A. Stefely et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
Jonathan B. Baell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Enhanced cell-surface stability of rescued ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones
Karoly Varga et al.
BIOCHEMICAL JOURNAL (2008)
Failure of cAMP agonists to activate rescued ΔF508 CFTR in CFBE41o- airway epithelial monolayers
Z Bebok et al.
JOURNAL OF PHYSIOLOGY-LONDON (2005)
Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains
O Moran et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
CFTR: Covalent and noncovalent modification suggests a role for fixed charges in anion conduction
SS Smith et al.
JOURNAL OF GENERAL PHYSIOLOGY (2001)
分享论文
